Navigation Links
Personalizing prostate specific antigen testing may improve specificity, reduce biopsies

New York, NY, April 14, 2013 Genetic variants have been identified which can increase serum prostate specific antigen (PSA) concentrations and prostate cancer risk. A new study published in The Journal of Urology reports that correcting PSA levels for these genetic variants can have significant consequences, including avoiding unnecessary biopsies for some men and eliminating false complacency for others.

In this study of 964 healthy Caucasian men, correcting individual PSA levels for these genetic variants led to an 18.3 percent reduction in the number of men who initially had a measured serum PSA above the biopsy criteria, but whose adjusted PSA fell below the cutoff value. The latter group would have likely undergone what would have been an unnecessary biopsy. Conversely, genetic correction led to PSA levels moving from below threshold to above threshold for 3.4 percent of the men, thus sending out an alert for further investigation.

"If our results are validated, adjustment for the four PSA single nucleotide polymorphisms (SNPs) could potentially prevent up to 15 percent to 20 percent of prostate biopsies. Since it has been estimated that more than 1 million biopsies are performed in the United States annually, this could translate into 150,000 to 200,000 potentially unnecessary biopsies every year," says William J. Catalona, MD, professor of urology at the Feinberg School of Medicine of Northwestern University. In addition to cost savings, fewer biopsies mean fewer adverse outcomes, such as infection, sepsis, and hospitalization.

For 98 percent of the men, genetic adjustment of PSA levels did not change outcome. However, genetic correction was important for the 17 men who were reclassified as no longer meeting biopsy criteria of PSA 2.5 ng/ml or greater and the three whose condition was up classified. The results suggest that traditional single cutoff PSA screening levels of 2.5 ng/ml or greater or 4.0 ng/ml or greater should be personalized to reflect an individual's genetic make-up.

"If confirmed, this approach could potentially be used to tailor PSA screening, possibly reducing unnecessary biopsies and avoiding delay in performing necessary biopsies," concludes Dr. Catalona and his co-investigators.


Contact: Linda Gruner
Elsevier Health Sciences

Related medicine news :

1. Personalizing medicine: New American Chemical Society Prized Science video
2. Personalizing biologic treatment to individual patients with rheuatoid arthritis is cost-effective
3. Can Selenium Lower Risk of Advanced Prostate Cancer?
4. Counting copy numbers characterises prostate cancer
5. Prostate cancer treatment study changing the way doctors practice
6. Intermittent Hormone Treatment for Prostate Cancer Not the Best
7. Black Men Often Face Delays in Prostate Cancer Care: Study
8. York scientists discover driving force behind prostate cancer
9. Is Early Baldness in Blacks a Clue to Prostate Cancer?
10. Early-onset baldness in African-American men may be linked to prostate cancer
11. Dennis R. Hill MD Announces Launch of High Dose Rate Brachytherapy of Prostate Cancer Website
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... ... process to promote standards of excellence for the field of eating disorders, announces ... 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... 13, 2017 , ... Talented host, actor Rob Lowe, is ... a new episode of "Success Files," which is an award-winning educational program broadcasted ... each subject in-depth with passion and integrity. , Sciatica occurs when the sciatic ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/19/2017)... 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically ... announced three leadership team developments today:   ... ... Tom ... Veteran medical device executive Josh Stopek , PhD, who ...
Breaking Medicine Technology: